This study is in progress, not accepting new patients

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

a study on HRAS Gene Mutation Head and Neck Squamous Cell Carcinoma Head and Neck Cancer Squamous Cell Carcinoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around

Description

Summary

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study including HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.

Official Title

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Details

KO-TIP-007 is an international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN). KO-TIP-007 has 2 study cohorts. The first study cohort, named AIM-HN, includes HNSCC subjects with HRAS mutations. AIM-HN subjects will receive treatment with tipifarnib and the outcome of this cohort will be evaluated for ORR by an independent review facility.

The second study cohort, SEQ-HN, is an observational sub-study including HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.

HNSCC patients in whom HRAS mutations are identified and who meet eligibility criteria will be offered participation in AIM-HN. HNSCC patients in whom HRAS mutations are not identified may participate in SEQ-HN only. These patients will be followed and the comparison of outcomes of HRAS mutant and HRAS wild type HNSCC will address the exploratory objective to determine the effect of HRAS mutation on the ORR of first line systemic therapy in patients with recurrent/metastatic HNSCC. Outcome data from subsequent lines of therapy will be collected.

Keywords

HRAS Gene Mutation, HNSCC, TIPIFARNIB, HEAD AND NECK CANCER, Squamous Cell Carcinoma of Head and Neck, HRAS Detection Assay, AIM-HN, SEQ-HN

Eligibility

You can join if…

Open to people ages 18 years and up

AIM-HN

  1. At least 18 years of age.
  2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) of squamous histology not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  3. Documented treatment failure from most recent prior therapy (e.g. tumor progression, clinical deterioration, or recurrence), and from at least one prior platinum-containing regimen, in any treatment setting.
  4. Known tumor missense HRAS mutation.
  5. Measurable disease by RECIST v1.1.
  6. ECOG performance status of 0-1.
  7. Acceptable liver, renal and hematological function
  8. Other protocol defined inclusion criteria may apply.

You CAN'T join if...

  1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (e.g. mucosal melanoma).
  2. Received treatment for unstable angina within prior year, myocardial infarction within the prior year, cerebro-vascular attack within the prior year, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  3. Non-tolerable Grade 2 or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
  4. Active, uncontrolled bacterial, viral or fungal infections requiring systemic therapy. Known history of infection with human immunodeficiency virus or an active infection with hepatitis B or hepatitis C.
  5. Received treatment for non-cancer related liver disease within prior year.
  6. Other protocol defined exclusion criteria may apply

Inclusion Criteria: SEQ-HN

  1. At least 18 years of age.
  2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary) of squamous histology.
  3. Will or has received at least one systemic anti-cancer therapy for recurrent or metastatic HNSCC.
  4. HRAS wildtype (i.e., have no identified tumor missense HRAS mutation).
  5. Other protocol defined inclusion criteria may apply

Exclusion Criteria: SEQ-HN

  1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or nonsquamous histologies (e.g. mucosal melanoma).
  2. Other protocol defined exclusion criteria may apply

Locations

  • UCLA - Jonsson Comprehensive Cancer Center
    Los Angeles California 90095 United States
  • UCSF - Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles California 90033 United States
  • The Oncology Institute of Hope and Innovation - Anaheim
    Whittier California 90603 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Kura Oncology, Inc.
ID
NCT03719690
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 284 study participants
Last Updated